Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 3, 2008, Pages 375-382

  Rehani, Kunal ^a   Scott, David A ^a   Renaud, Diane ^a   Hamza, Hashir ^a   Williams, Lisa R ^a   Wang, Huizhi ^a   Martin, Michael ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

Cholinergic anti inflammatory pathway; Cotinine; Cytokine; Inflammation; Monocyte; PI3K dependent anti inflammatory pathway; Tobacco smoking

Indexed keywords

BUNGAROTOXIN RECEPTOR; COTININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; NICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P40; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENETIC TRANSCRIPTION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; INNATE IMMUNITY; MONOCYTE; PHENOTYPE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELLS, CULTURED; CHOLINERGIC AGENTS; COTININE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; NF-KAPPA B; RECEPTORS, CHOLINERGIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

NEGIBACTERIA; NICOTIANA TABACUM;

EID: 39149125131     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.12.003     Document Type: Article

References (41)

1. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat. Rev. Drug Discov. 4 (2005) 673-684
2. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
3. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., Wang H., Abumrad N., Eaton J.W., and Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
4. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., Al-Abed Y., Wang H., Metz C., Miller E.J., Tracey K.J., and Ulloa L. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10 (2004) 1216-1221
5. Matsunaga K., Klein T.W., Friedman H., and Yamamoto Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J. Immunol. 167 (2001) 6518-6524
6. Scott D.A., Palmer R.M., and Stapleton J.A. Validation of smoking status in clinical research into inflammatory periodontal disease. J. Clin. Periodontol. 28 (2001) 715-722
7. Dwoskin L.P., Teng L., Buxton S.T., and Crooks P.A. (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther. 288 (1999) 905-911
8. Terry Jr. A.V., Hernandez C.M., Hohnadel E.J., Bouchard K.P., and Buccafusco J.J. Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 11 (2005) 229-252
9. Srivastava E.D., Hallett M.B., and Rhodes J. Effect of nicotine and cotinine on the production of oxygen free radicals by neutrophils in smokers and non-smokers. Hum. Toxicol. 8 (1989) 461-463
10. Benowitz N.L., Kuyt F., Jacob III P., Jones R.T., and Osman A.L. Cotinine disposition and effects. Clin. Pharmacol. Ther. 34 (1983) 604-611
11. Zevin S., Jacob P., Geppetti P., and Benowitz N.L. Clinical pharmacology of oral cotinine. Drug Alcohol Depend. 60 (2000) 13-18
12. Hatsukami D.K., Grillo M., Pentel P.R., Oncken C., and Bliss R. Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol. Biochem. Behav. 57 (1997) 643-650
13. Martin M., Rehani K., Jope R.S., and Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6 (2005) 777-784
14. Martin M., Schifferle R.E., Cuesta N., Vogel S.N., Katz J., and Michalek S.M. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J. Immunol. 171 (2003) 717-725
15. Hogg R.C., Raggenbass M., and Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev. Physiol. Biochem. Pharmacol. 147 (2003) 1-46
16. Gotti C., and Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 74 (2004) 363-396
17. Peng X., Katz M., Gerzanich V., Anand R., and Lindstrom J. Human alpha7 acetylcholine receptor: cloning of the alpha7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha7 homomers expressed in Xenopus oocytes. Mol. Pharmacol. 45 (1994) 546-554
18. Drisdel R.C., and Green W.N. Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers. J. Neurosci. 20 (2000) 133-139
19. Huston J.M., Ochani M., Rosas-Ballina M., Liao H., Ochani K., Pavlov V.A., Gallowitsch-Puerta M., Ashok M., Czura C.J., Foxwell B., Tracey K.J., and Ulloa L. Splenectomy inactivates the cholinergic anti-inflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 203 (2006) 1623-1628
20. de Jonge W.J., and Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol. (2007)
21. Scott D.A., and Martin M. Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases. World J. Gastroenterol. 12 (2006) 7451-7459
22. Pavlov V.A., and Tracey K.J. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem. Soc. Trans. 34 (2006) 1037-1040
23. Gallowitsch-Puerta M., and Pavlov V.A. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci. 80 (2007) 2325-2329
24. Libert C. Inflammation: a nervous connection. Nature 421 (2003) 328-329
25. Pavlov V.A., Ochani M., Yang L.H., Gallowitsch-Puerta M., Ochani K., Lin X., Levi J., Parrish W.R., Rosas-Ballina M., Czura C.J., Larosa G.J., Miller E.J., Tracey K.J., and Al-Abed Y. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 35 (2007) 1139-1144
26. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol. Neurobiol. 15 (1997) 193-222
27. Villiger Y., Szanto I., Jaconi S., Blanchet C., Buisson B., Krause K.H., Bertrand D., and Romand J.A. Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J. Neuroimmunol. 126 (2002) 86-98
28. Chen D., and Patrick J.W. The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the alpha7 subunit. J. Biol. Chem. 272 (1997) 24024-24029
29. Bertrand D., Galzi J.L., Devillers-Thiery A., Bertrand S., and Changeux J.P. Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6971-6975
30. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2 (2002) 725-734
31. Li Q., Withoff S., and Verma I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 26 (2005) 318-325
32. Raetz C.R., and Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71 (2002) 635-700
33. Medzhitov R., and Janeway Jr. C. Innate immunity. N. Engl. J. Med. 343 (2000) 338-344
34. Beutler B., and Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57 (1988) 505-518
35. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 77 (1991) 1627-1652
36. Chen C., Cowan J.C., Hasday J.D., Vogel S.V., and Medvedev A.E. Smoking inhibits expression of proinflammatory cytokines and activation of Irak-1, p38 and NF-kB in alveolar macrophages stimulated with TLR2 and TLR4 agonists (Abstract). J. Immunol. 178 (2007) 40-48
37. Sugano N., Shimada K., Ito K., and Murai S. Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochem. Biophys. Res. Commun. 252 (1998) 25-28
38. Franke T.F., Kaplan D.R., Cantley L.C., and Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 (1997) 665-668
39. Stokoe D.L.R., Stephens L.R., Copeland T., Piers R., Gaffney J., Reese C.B., Painter G.F., Holmes A.B., McCormick F., and Hawkins P.T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277 (1997) 567-570
40. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J. Cell. Sci. 114 (2001) 2903-2910
41. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789